Xiaolei Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaolei Wei has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Yongqiang Wei
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 shared publications - Ru Feng
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 shared publications - Weimin Huang
Orthopedic Department, 960 Hospital of People’s Liberation Army, Jinan, People’s Republic of China
2 shared publications - Bihui Hilda Ye
Albert Einstein College of Medicine
1 shared publication - Chen-Yang Liao
Hangzhou Medimscience Biomedical Technology Co. Ltd., Hangzhou, China
1 shared publication - Cheng Zhong
Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in SSRN Electronic Journal
Continuous BTK inhibition versus fixed-duration therapy in untreated CLL: a network meta-analysis
Continuous BTK inhibitor (BTKi) therapy and fixed-duration venetoclax-based regimens are standard first-line options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but their relative benefit remains uncertain. We performed a systematic review and network meta-analysis in treatment-naive CLL/SLL comparing four treatment-class nodes: continuous BTKi monotherapy, fixed-duration venetoclax-obinutuzumab (Ven-Obi), fixed-duration venetoclax-BTKi (Ven-BTKi), and chemoimmunotherapy (CIT). The primary endpoint was progression-free survival (PFS). Prespecified subgroup analyses were performed for unmutated IGHV and TP53 mutation/del(17p). Eight phase 3 trials contributed nine treatment contrasts to the main network. In the overall population, no statistically significant PFS difference was observed among targeted strategies: BTKi vs Ven-Obi, hazard ratio (HR) 0.90 (95% confidence interval [CI], 0.51-1.59); BTKi vs Ven-BTKi, HR 0.95 (95% CI, 0.55-1.65); and Ven-Obi vs Ven-BTKi, HR 1.06 (95% CI, 0.53-2.10). All targeted strategies improved PFS compared with CIT. BTKi ranked highest by P-score overall and in unmutated IGHV disease, but confidence intervals among targeted strategies overlapped. TP53 mutation/del(17p) analyses were exploratory. Safety profiles differed by regimen: BTKi monotherapy had less high-grade neutropenia, whereas ibrutinib-containing regimens showed cardiac safety signals. In treatment-naive CLL/SLL, current randomized evidence did not show a statistically significant difference in PFS among continuous BTKi, fixed-duration Ven-Obi, and fixed-duration Ven-BTKi. CIT was consistently the least favorable strategy. Treatment selection among targeted strategies should therefore be guided by genomic risk, toxicity, treatment duration, monitoring feasibility, and patient preference.
- 24 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessContinuous BTK inhibition versus fixed-duration therapy in untreated CLL: a network meta-analysis
Continuous BTK inhibitor (BTKi) therapy and fixed-duration venetoclax-based regimens are standard first-line options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but their relative benefit remains uncertain. We performed a systematic review and network meta-analysis in treatment-naive CLL/SLL comparing four treatment-class nodes: continuous BTKi monotherapy, fixed-duration venetoclax-obinutuzumab (Ven-Obi), fixed-duration venetoclax-BTKi (Ven-BTKi), and chemoimmunotherapy (CIT). The primary endpoint was progression-free survival (PFS). Prespecified subgroup analyses were performed for unmutated IGHV and TP53 mutation/del(17p). Eight phase 3 trials contributed nine treatment contrasts to the main network. In the overall population, no statistically significant PFS difference was observed among targeted strategies: BTKi vs Ven-Obi, hazard ratio (HR) 0.90 (95% confidence interval [CI], 0.51-1.59); BTKi vs Ven-BTKi, HR 0.95 (95% CI, 0.55-1.65); and Ven-Obi vs Ven-BTKi, HR 1.06 (95% CI, 0.53-2.10). All targeted strategies improved PFS compared with CIT. BTKi ranked highest by P-score overall and in unmutated IGHV disease, but confidence intervals among targeted strategies overlapped. TP53 mutation/del(17p) analyses were exploratory. Safety profiles differed by regimen: BTKi monotherapy had less high-grade neutropenia, whereas ibrutinib-containing regimens showed cardiac safety signals. In treatment-naive CLL/SLL, current randomized evidence did not show a statistically significant difference in PFS among continuous BTKi, fixed-duration Ven-Obi, and fixed-duration Ven-BTKi. CIT was consistently the least favorable strategy. Treatment selection among targeted strategies should therefore be guided by genomic risk, toxicity, treatment duration, monitoring feasibility, and patient preference.
- Top Cited Papers
- 13 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (108) , eadn4302
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance
Cancer immunotherapies exhibit impressive efficacy in some cancers but show only limited benefits for refractory hematological malignancies. The complex immune escape mechanisms of hematological cancers remain unclear. Here, we found that P-selectin glycoprotein ligand 1 (PSGL-1) was highly expressed by hematological cancers and negatively correlated with cancer prognosis. PSGL-1 deficiency in tumors suppressed the progression of multiple mouse models of hematological cancer by promoting infiltration of macrophages and their phagocytic activity. Tumor PSGL-1 inhibited the interaction between tumor ICAM-1 and CD11a/CD18 integrin (LFA-1) in macrophages, thereby suppressing prophagocytic signaling downstream of LFA-1. A humanized antibody targeting human PSGL-1 (αhPSGL-1) efficiently triggered macrophage phagocytosis of human hematological malignancies in vitro and slowed cancer progression in vivo. Additionally, PSGL-1 blockade potentiated the efficacy of doxorubicin chemotherapy and anti-CD47 and anti-CD38 antibody therapy. Therefore, PSGL-1 is a previously undescribed phagocytosis checkpoint, and targeting PSGL-1 could be a promising immunotherapy strategy for treating hematological malignancies.
- 13 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (108) , eadn4302
Top Cited PapersPSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance
Cancer immunotherapies exhibit impressive efficacy in some cancers but show only limited benefits for refractory hematological malignancies. The complex immune escape mechanisms of hematological cancers remain unclear. Here, we found that P-selectin glycoprotein ligand 1 (PSGL-1) was highly expressed by hematological cancers and negatively correlated with cancer prognosis. PSGL-1 deficiency in tumors suppressed the progression of multiple mouse models of hematological cancer by promoting infiltration of macrophages and their phagocytic activity. Tumor PSGL-1 inhibited the interaction between tumor ICAM-1 and CD11a/CD18 integrin (LFA-1) in macrophages, thereby suppressing prophagocytic signaling downstream of LFA-1. A humanized antibody targeting human PSGL-1 (αhPSGL-1) efficiently triggered macrophage phagocytosis of human hematological malignancies in vitro and slowed cancer progression in vivo. Additionally, PSGL-1 blockade potentiated the efficacy of doxorubicin chemotherapy and anti-CD47 and anti-CD38 antibody therapy. Therefore, PSGL-1 is a previously undescribed phagocytosis checkpoint, and targeting PSGL-1 could be a promising immunotherapy strategy for treating hematological malignancies.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4337
CD30 Promotes Proliferation Via ERK 1/2 and p38 MAPK Signal Pathways in ABC-Diffuse Large B Cell Lymphoma
Background CD30 was expressed in about 40% diffuse large B cell lymphoma (DLBCL), epically in activated B cell subtype DLBCL(ABC-DLBCL) and implied superior outcome. however, the underlying mechanisms remains unclear. Methods Three ABC-DLBCL cell lines (SuDHL2, TMD8, HBL1) were used for construction of stably CD30 expression cell lines. The proliferation of these cell lines was measured by MTT assay. Cell cycles were detected by Flow Cytometry after staining with PI. Expression of CyclinD1, p27, CDK2, ERK, phosphorylation-ERK, p38, phosphorylation p38 was detected by Western Blot. Nude mice were used in vivo study. Results With CD30 overexpression, the proliferation and division of SuDHL2, TMD8 and HBL1 cell lines were promoted. CyclilnD1, CDK2 were upregulated and p27 was downregulated after of CD30 overexpression. Furthermore, CD30 was knock down by treated CD30 shRNA in CD30 overexpression cell lines. CD30 KD could reverse the the proliferation induced by CD30 expression. CD30 overexpression increased the phosphorylation of ERK and p38 in ABC-DLBCL cells. In vivo study, CD30 overexpression was correlated with cell proliferation and division. Conclusion Taken together, our date showed CD30 promotes proliferation and division by activating ERK 1/2 and p38 MAPK signal pathways, and targeting CD30 may be a novel therapeutic approach for improving the effectiveness of chemotherapy in ABC-DLBCLs. Key words: CD30, ERK 1/2, p38 MAPK, ABC- diffuse large B cell lymphoma
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4337
Open AccessCD30 Promotes Proliferation Via ERK 1/2 and p38 MAPK Signal Pathways in ABC-Diffuse Large B Cell Lymphoma
Background CD30 was expressed in about 40% diffuse large B cell lymphoma (DLBCL), epically in activated B cell subtype DLBCL(ABC-DLBCL) and implied superior outcome. however, the underlying mechanisms remains unclear. Methods Three ABC-DLBCL cell lines (SuDHL2, TMD8, HBL1) were used for construction of stably CD30 expression cell lines. The proliferation of these cell lines was measured by MTT assay. Cell cycles were detected by Flow Cytometry after staining with PI. Expression of CyclinD1, p27, CDK2, ERK, phosphorylation-ERK, p38, phosphorylation p38 was detected by Western Blot. Nude mice were used in vivo study. Results With CD30 overexpression, the proliferation and division of SuDHL2, TMD8 and HBL1 cell lines were promoted. CyclilnD1, CDK2 were upregulated and p27 was downregulated after of CD30 overexpression. Furthermore, CD30 was knock down by treated CD30 shRNA in CD30 overexpression cell lines. CD30 KD could reverse the the proliferation induced by CD30 expression. CD30 overexpression increased the phosphorylation of ERK and p38 in ABC-DLBCL cells. In vivo study, CD30 overexpression was correlated with cell proliferation and division. Conclusion Taken together, our date showed CD30 promotes proliferation and division by activating ERK 1/2 and p38 MAPK signal pathways, and targeting CD30 may be a novel therapeutic approach for improving the effectiveness of chemotherapy in ABC-DLBCLs. Key words: CD30, ERK 1/2, p38 MAPK, ABC- diffuse large B cell lymphoma
- Open Access
- 31 August 2021
- Published by Springer Nature in Research Square
Inhibiting The xCT Antiporter Sensitizes High Risk DLBCL to Doxorubicin-Containing Therapy
Background. Although outcomes in diffuse large B-cell lymphoma (DLBCL) have dramatically improved following the introduction of R-CHOP two decades ago, one-third of the patients fail to attain durable remission and require salvage and additional therapies. Many attempts to improve upon R-CHOP efficacy by incorporating targeted agents have failed, suggesting a need to better understand the mechanisms underlying R-CHOP resistance/responsiveness. We have previously reported that Doxorubicin (Dox), the main cytotoxic ingredient in CHOP, has subtype-specific mechanisms of cytotoxicity in DLBCLs due to differences in its subcellular distribution pattern. Specifically, Dox-induced cytotoxicity in the therapy refractory ABC-DLBCLs is largely dependent on oxidative stress rather than the DNA damage response. These findings suggest that R-CHOP outcome could be modulated by manipulating oxidative stress response in DLBCL cells. This study focuses on xCT, the light chain of the cystine/glutamate antiporter xc` that controls the rate-limiting step for glutathione (GSH) biosynthesis. We demonstrate novel roles of the xCT-GSH-ROS axis in maintenance and therapeutic response of high risk DLBCLs. Methods. Prognostic significance of xCT protein expression in a cohort of 87 DLBCL patients treated with R-CHOP were evaluated. Dynamic changes of the cellular GSH pool to Dox treatment were examined. xCT inhibition was achieved using a small molecular inhibitor sulfasalazine (SASP) and through shRNA-mediated knock-down. The ability of SASP to sensitize ABC-DLBCL/double-hit lymphomas to Dox-containing therapy was investigated in cell line and NSG-based xenograft models. Results. Dox elicits a rapid antioxidant response characterized by a GSH spike that can be eliminated by suppressing the xCT antiporter function. Mechanistically, xCT inhibition depleted the total GSH pool and markedly enhanced the p38-dependent apoptosis response following Dox treatment. Furthermore, supporting a role of the xCT-GSH axis in clinical response to Dox-containing therapies, xCT expression predicts poor prognosis among ABC-DLBCL but not GCB-DLBCL patients treated with R-CHOP. Finally, we demonstrate that combinatorial treatment with Dox and SASP produced marked synergy in xenograft models for ABC-DLBCL/double-hit lymphomas. Conclusions. In ABC-DLBCL, the xCT-GSH-p38 axis plays a critical role in survival response to Dox-containing therapies. xCT inhibition may hold significant promise to improve the first-line treatment outcome of patients with high risk DLBCL.
- 31 August 2021
- Published by Springer Nature in Research Square
Open AccessInhibiting The xCT Antiporter Sensitizes High Risk DLBCL to Doxorubicin-Containing Therapy
Background. Although outcomes in diffuse large B-cell lymphoma (DLBCL) have dramatically improved following the introduction of R-CHOP two decades ago, one-third of the patients fail to attain durable remission and require salvage and additional therapies. Many attempts to improve upon R-CHOP efficacy by incorporating targeted agents have failed, suggesting a need to better understand the mechanisms underlying R-CHOP resistance/responsiveness. We have previously reported that Doxorubicin (Dox), the main cytotoxic ingredient in CHOP, has subtype-specific mechanisms of cytotoxicity in DLBCLs due to differences in its subcellular distribution pattern. Specifically, Dox-induced cytotoxicity in the therapy refractory ABC-DLBCLs is largely dependent on oxidative stress rather than the DNA damage response. These findings suggest that R-CHOP outcome could be modulated by manipulating oxidative stress response in DLBCL cells. This study focuses on xCT, the light chain of the cystine/glutamate antiporter xc` that controls the rate-limiting step for glutathione (GSH) biosynthesis. We demonstrate novel roles of the xCT-GSH-ROS axis in maintenance and therapeutic response of high risk DLBCLs. Methods. Prognostic significance of xCT protein expression in a cohort of 87 DLBCL patients treated with R-CHOP were evaluated. Dynamic changes of the cellular GSH pool to Dox treatment were examined. xCT inhibition was achieved using a small molecular inhibitor sulfasalazine (SASP) and through shRNA-mediated knock-down. The ability of SASP to sensitize ABC-DLBCL/double-hit lymphomas to Dox-containing therapy was investigated in cell line and NSG-based xenograft models. Results. Dox elicits a rapid antioxidant response characterized by a GSH spike that can be eliminated by suppressing the xCT antiporter function. Mechanistically, xCT inhibition depleted the total GSH pool and markedly enhanced the p38-dependent apoptosis response following Dox treatment. Furthermore, supporting a role of the xCT-GSH axis in clinical response to Dox-containing therapies, xCT expression predicts poor prognosis among ABC-DLBCL but not GCB-DLBCL patients treated with R-CHOP. Finally, we demonstrate that combinatorial treatment with Dox and SASP produced marked synergy in xenograft models for ABC-DLBCL/double-hit lymphomas. Conclusions. In ABC-DLBCL, the xCT-GSH-p38 axis plays a critical role in survival response to Dox-containing therapies. xCT inhibition may hold significant promise to improve the first-line treatment outcome of patients with high risk DLBCL.
- RetractedOpen Access
- 1 April 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3589-3599
LINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p
Introduction: Emerging evidence has revealed that long noncoding RNA (lncRNA) play important role in almost all kinds of human cancers. LINC00908 has been reported to be involved in the development of prostate cancer, colorectal cancer and gastric cancer which was functioned as an oncogene. However, the potential biology role and molecular mechanism of LINC00908 in diffuse large B-cell lymphoma are still unclear. Methods: LINC00908 and miR-671-5p expression were evaluated in DLBCL tissues and cell lines using RT-qPCR. CCK-8 and transwell assay were used to analyze the in vitro role of LINC00908 in DLBCL progression. The xenograft model was used to explore the in vivo role of LINC00908 in DLBCL growth. The physical interaction between LINC00908 and miR-671-5p was confirmed using bioinformatics analysis and a dual luciferase assay, RIP and RNA pull down. Results: The expression of LINC00908 was markedly up-regulated in diffuse large B-cell lymphoma tissues and cell lines, and the decreased expression of LINC00908 significantly inhibited diffuse large B-cell lymphoma cell proliferation and invasion. Then, we revealed that LINC00908 directly interacted with miR-671-5p, which was down-regulated in diffuse large B-cell lymphoma cells and highly expressed with LINC00908 knockdown. Moreover, luciferase reporter assays and RNA immunoprecipitation (RIP) assay further proved that miR-671-5p is a direct target of LINC00908 in diffuse large B-cell lymphoma cells. Rescue experiments were also performed, and we confirmed that LINC00908 acts as an oncogene role in diffuse large B-cell lymphoma through miR-671-5p. Finally, the influence of LINC00908 silence significantly inhibited diffuse large B-cell lymphoma growth in vivo. Conclusion: LINC00908 promotes malignancy of diffuse large B-cell lymphoma through regulating miR-671-5p.
- 1 April 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3589-3599
RetractedOpen AccessLINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p
Introduction: Emerging evidence has revealed that long noncoding RNA (lncRNA) play important role in almost all kinds of human cancers. LINC00908 has been reported to be involved in the development of prostate cancer, colorectal cancer and gastric cancer which was functioned as an oncogene. However, the potential biology role and molecular mechanism of LINC00908 in diffuse large B-cell lymphoma are still unclear. Methods: LINC00908 and miR-671-5p expression were evaluated in DLBCL tissues and cell lines using RT-qPCR. CCK-8 and transwell assay were used to analyze the in vitro role of LINC00908 in DLBCL progression. The xenograft model was used to explore the in vivo role of LINC00908 in DLBCL growth. The physical interaction between LINC00908 and miR-671-5p was confirmed using bioinformatics analysis and a dual luciferase assay, RIP and RNA pull down. Results: The expression of LINC00908 was markedly up-regulated in diffuse large B-cell lymphoma tissues and cell lines, and the decreased expression of LINC00908 significantly inhibited diffuse large B-cell lymphoma cell proliferation and invasion. Then, we revealed that LINC00908 directly interacted with miR-671-5p, which was down-regulated in diffuse large B-cell lymphoma cells and highly expressed with LINC00908 knockdown. Moreover, luciferase reporter assays and RNA immunoprecipitation (RIP) assay further proved that miR-671-5p is a direct target of LINC00908 in diffuse large B-cell lymphoma cells. Rescue experiments were also performed, and we confirmed that LINC00908 acts as an oncogene role in diffuse large B-cell lymphoma through miR-671-5p. Finally, the influence of LINC00908 silence significantly inhibited diffuse large B-cell lymphoma growth in vivo. Conclusion: LINC00908 promotes malignancy of diffuse large B-cell lymphoma through regulating miR-671-5p.
- Open Access
- 27 January 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma
The prognostic value of albumin changes between diagnosis and end-of-treatment (EoT) in diffuse large B-cell lymphoma (DLBCL) remains unknown. We retrospectively analyzed 574 de novo DLBCL patients treated with R-CHOP from our and two other centers. All patients were divided into a training cohort (n = 278) and validation cohort (n = 296) depending on the source of the patients. Overall survival (OS) and progression-free survival (PFS) were analyzed by the method of Kaplan–Meier and Cox proportional hazard regression model. In the training cohort, 163 (58.6%) patients had low serum albumin at diagnosis, and 80 of them were present with consecutive hypoalbuminemia at EoT. Patients with consecutive hypoalbuminemia showed inferior OS and PFS (p = 0.010 and p = 0.079, respectively). Similar survival differences were also observed in the independent validation cohort (p = 0.006 and p = 0.030, respectively). Multivariable analysis revealed that consecutive hypoalbuminemia was an independent prognostic factor OS [relative risk (RR), 2.249; 95% confidence interval (CI), 1.441–3.509, p < 0.001] and PFS (RR, 2.001; 95% CI, 1.443–2.773, p < 0.001) in all DLBCL patients independent of IPI. In conclusion, consecutive hypoalbuminemia is a simple and effective adverse prognostic factor in patients with DLBCL, which reminds us to pay more attention to patients with low serum albumin at EoT during follow-up.
- 27 January 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Open AccessConsecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma
The prognostic value of albumin changes between diagnosis and end-of-treatment (EoT) in diffuse large B-cell lymphoma (DLBCL) remains unknown. We retrospectively analyzed 574 de novo DLBCL patients treated with R-CHOP from our and two other centers. All patients were divided into a training cohort (n = 278) and validation cohort (n = 296) depending on the source of the patients. Overall survival (OS) and progression-free survival (PFS) were analyzed by the method of Kaplan–Meier and Cox proportional hazard regression model. In the training cohort, 163 (58.6%) patients had low serum albumin at diagnosis, and 80 of them were present with consecutive hypoalbuminemia at EoT. Patients with consecutive hypoalbuminemia showed inferior OS and PFS (p = 0.010 and p = 0.079, respectively). Similar survival differences were also observed in the independent validation cohort (p = 0.006 and p = 0.030, respectively). Multivariable analysis revealed that consecutive hypoalbuminemia was an independent prognostic factor OS [relative risk (RR), 2.249; 95% confidence interval (CI), 1.441–3.509, p < 0.001] and PFS (RR, 2.001; 95% CI, 1.443–2.773, p < 0.001) in all DLBCL patients independent of IPI. In conclusion, consecutive hypoalbuminemia is a simple and effective adverse prognostic factor in patients with DLBCL, which reminds us to pay more attention to patients with low serum albumin at EoT during follow-up.